Because long term pharmacological blockade of D2 receptors may be poorly tolerated in patients [55], [56], the inclusion of Rho/ROCK inhibitors could be an interesting therapeutic option to target the vulnerability of D2-R expressing striatal neurons in HD. This evidence concerns the gene RHO and Huntington disease.